

PCT/EP98/00367
WAGNER, Hermann et al.
Our Ref.: C 1020 PCT

VOSSIUS & PARTNER
PATENTANWÄLTE
SIEBERTSTR. 4
81675 MÜNCHEN

02. Juli 1999

Claims

1. A pharmaceutical composition, comprising:
 - (a) at least one polynucleotide, wherein the polynucleotide comprises the sequence of a binding site of a transcription factor and has a nucleic acid sequence of any one of SEQ ID NO: 8 (GATTGCCTGA CGTCAGAGAG), SEQ ID NO: 9 (GGAATGACGT TCCCTGTG), SEQ ID NO: 10 (AGCTATGACG TTCCAAGG), SEQ ID NO: 11 (GCTTGATGAC TCAGCCGGAA), SEQ ID NO: 12 (TCGATCGGGG CGGGGCGAGC), SEQ ID NO: 13 (TGCAGATTGC GCAATCTGCA), SEQ ID NO: 14 (AGCGGGGGCG AGCGGGGGCG), SEQ ID NO: 16 (GTCCATTTCC CGTAAATCTT), SEQ ID NO: 17 (TATGCATATT CCTGTAAGTG), SEQ ID NO: 19 (CTGATTTCCC CGAAATGATG), SEQ ID NO: 20 (AGATTTCTAG GAATTCAATC), SEQ ID NO: 21 (GTATTTCCCA GAAAAGGAAC), SEQ ID NO: 22 (AAGCGAAAAT GAAATTGACT), and SEQ ID NO: 23 (CAGGCATAAC GGTTCCGTAG);
 - (b) at least one antigen; and
 - (c) a pharmaceutically acceptable carrier and/or diluent.
2. The composition according to claim 1 characterized in that the polynucleotide comprises at least one phosphorothioate linkage.
3. Pharmaceutical composition according to any one of the preceding claims characterized in that the antigen (b) is selected from the group comprising peptides, polypeptides, proteins, polysaccharides, steroids and tumor cells.

AMENDED SHEET